fenofibrate has been researched along with Liver Steatosis in 45 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effect of fenofibrate on the clinical, analytical and histological evolution of patients with non-alcoholic fatty liver disease." | 9.13 | A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. ( Colina, F; Fernández-Miranda, C; López-Alonso, G; Pérez-Carreras, M; Solís-Herruzo, JA; Vargas, C, 2008) |
| " Using mice with fenofibrate-induced fatty liver as a model system, the effects of uridine on liver lipid metabolism are examined." | 7.80 | Uridine prevents fenofibrate-induced fatty liver. ( Le, TT; Pizzorno, G; Urasaki, Y, 2014) |
| "The objectives of this study were to determine the effect of osthole on the insulin resistance (IR) in high-fat and high-sucrose-induced fatty liver rats and to investigate its potential mechanisms." | 7.77 | Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats. ( Qi, Z; Wang, H; Xie, M; Xue, J; Zhang, Y, 2011) |
| "To study the effects of osthole on hyperlipidemic fatty liver and investigate the possible mechanisms." | 7.74 | Therapeutic effect of osthole on hyperlipidemic fatty liver in rats. ( Gu, ZL; Xie, ML; Zhang, Y; Zhu, LJ, 2007) |
| "Effects of bifendate, a synthetic intermediate of schisandrin C (a dibenzocyclooctadiene derivative), on liver lipid contents were investigated in experimentally-induced hypercholesterolemia in mice." | 7.73 | Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. ( Dong, H; Ko, KM; Pan, SY; Yang, R; Yu, ZL, 2006) |
| "After treatment by fenofibrate, in the serum of rats with alcoholic fatty liver, the level of TG decreased significantly (1." | 7.72 | [Therapy effects of fenofibrate on alcoholic fatty liver and drug-induced fatty liver in rats]. ( Jia, XQ; Lu, RJ; Meng, FL; Yan, M; Zhao, XC, 2003) |
| "Fenofibrate treatment remarkably improved microvascular patency, tissue oxygenation and redox states in the affected liver." | 5.36 | Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice. ( Aizawa, M; Goda, N; Kondo, K; Morimoto, M; Shimizu, K; Suematsu, M; Sugioka, T; Takizawa, M; Tsukada, K, 2010) |
| "To evaluate the effect of fenofibrate on the clinical, analytical and histological evolution of patients with non-alcoholic fatty liver disease." | 5.13 | A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. ( Colina, F; Fernández-Miranda, C; López-Alonso, G; Pérez-Carreras, M; Solís-Herruzo, JA; Vargas, C, 2008) |
| " Mice with diet-induced obesity were treated with the PPARγ or PPARα agonist, pioglitazone or fenofibrate, respectively." | 3.83 | Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver. ( Jia, WP; Wang, C; Zhang, ML; Zhong, Y; Zhu, YX, 2016) |
| " Using mice with fenofibrate-induced fatty liver as a model system, the effects of uridine on liver lipid metabolism are examined." | 3.80 | Uridine prevents fenofibrate-induced fatty liver. ( Le, TT; Pizzorno, G; Urasaki, Y, 2014) |
| " Treatment of high fat diet-induced obese mice with T0901317, an LXR activator, or fenofibrate, the PPARα agonist, or in combination alleviated insulin resistance and improved glucose tolerance." | 3.79 | Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice. ( Bu, L; Gao, M; Liu, D; Ma, Y, 2013) |
| "The objectives of this study were to determine the effect of osthole on the insulin resistance (IR) in high-fat and high-sucrose-induced fatty liver rats and to investigate its potential mechanisms." | 3.77 | Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats. ( Qi, Z; Wang, H; Xie, M; Xue, J; Zhang, Y, 2011) |
| " We followed the spontaneous evolution of liver steatosis and tested the therapeutic usefulness of metformin and fenofibrate in a model of steatosis, the Zucker diabetic fatty (ZDF) rat." | 3.75 | Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate. ( Abdallah, P; Basset, A; Beylot, M; del Carmine, P; Forcheron, F; Haffar, G, 2009) |
| "To study the effects of osthole on hyperlipidemic fatty liver and investigate the possible mechanisms." | 3.74 | Therapeutic effect of osthole on hyperlipidemic fatty liver in rats. ( Gu, ZL; Xie, ML; Zhang, Y; Zhu, LJ, 2007) |
| " The major aim of this study was to establish a novel NASH mouse model accompanied by obesity and insulin resistance, then explore the molecular mechanisms of NASH and evaluate the effects of both the peroxisome proliferator-activated receptor alpha (PPARalpha) agonist fenofibrate and the PPARgamma agonist rosiglitazone in this established NASH model." | 3.74 | The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. ( Cong, WN; Liu, GT; Tao, RY; Tian, JY; Ye, F, 2008) |
| "Effects of bifendate, a synthetic intermediate of schisandrin C (a dibenzocyclooctadiene derivative), on liver lipid contents were investigated in experimentally-induced hypercholesterolemia in mice." | 3.73 | Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. ( Dong, H; Ko, KM; Pan, SY; Yang, R; Yu, ZL, 2006) |
| "After treatment by fenofibrate, in the serum of rats with alcoholic fatty liver, the level of TG decreased significantly (1." | 3.72 | [Therapy effects of fenofibrate on alcoholic fatty liver and drug-induced fatty liver in rats]. ( Jia, XQ; Lu, RJ; Meng, FL; Yan, M; Zhao, XC, 2003) |
| "Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common causes of elevated liver enzymes in the general population." | 2.49 | Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. ( Aramin, H; Eslami, L; Malekzadeh, R; Merat, S; Nasseri-Moghaddam, S, 2013) |
| "Since human steatohepatitis (both the alcoholic and non-alcoholic type) is characterized by reduced expression of PPARα and disturbed lipid metabolism we investigated the role of this ligand-activated receptor in the development of DDC-induced liver injury." | 1.48 | The PPARα Agonist Fenofibrate Prevents Formation of Protein Aggregates (Mallory-Denk bodies) in a Murine Model of Steatohepatitis-like Hepatotoxicity. ( Abuja, PM; Denk, H; Kratky, D; Lahiri, P; Nikam, A; Patankar, JV; Sachdev, V; Somlapura, M; Zatloukal, K, 2018) |
| "Fenofibrate treatment induced mature SREBP-1c expression via the direct binding of PPARα to the DR1 motif of the SREBP-1c gene." | 1.40 | Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect. ( Cao, M; Chen, W; Gao, L; Jing, F; Wang, Q; Wang, T; Xu, C; Yan, F; Yu, C; Zhao, J; Zhou, X, 2014) |
| "Fenofibrate treatment increased fatty acid metabolism further, which reduced postburn hepatic steatosis (burn versus sham P < 0." | 1.39 | Fenofibrate does not affect burn-induced hepatic endoplasmic reticulum stress. ( Arno, A; Hiyama, Y; Jeschke, MG; Kraft, R; Marshall, AH, 2013) |
| "Hyperlipidemia is referred to as hypercholesterolemia, hypertriglyceridemia, or both in combined hyperlipidemia." | 1.39 | Novel mouse model of combined hyperlipidemia associated with steatosis and liver injury by a single-dose intragastric administration of schisandrin B/cholesterol/bile salts mixture. ( Jia, ZH; Ko, KM; Pan, SY; Sun, N; Wang, XY; Yu, Q; Yu, ZL; Zhang, Y; Zhu, PL, 2013) |
| "Fenofibrate is a drug used to treat hyperlipidaemia that works by inhibiting hepatic triacylglycerol synthesis." | 1.39 | cAMP response element binding protein H mediates fenofibrate-induced suppression of hepatic lipogenesis. ( Choi, YK; Go, Y; Jeong, JY; Kim, YD; Lee, IK; Min, AK; Park, KG, 2013) |
| "Fenofibrate treatment remarkably improved microvascular patency, tissue oxygenation and redox states in the affected liver." | 1.36 | Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice. ( Aizawa, M; Goda, N; Kondo, K; Morimoto, M; Shimizu, K; Suematsu, M; Sugioka, T; Takizawa, M; Tsukada, K, 2010) |
| "Fenofibrate treatment preserved AdipoR2 and phosphorylated AMPK (pAMPK) levels in palmitate-treated cells accompanied by reduced triglyceride (TG) accumulation and less activation of ER stress markers CCAAT/enhancer binding (C/EBPbeta) and eukaryotic translation initiation factor 2 alpha." | 1.35 | Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis. ( Friedman, JE; Janssen, RC; Qadri, I; Rahman, SM, 2009) |
| "Fenofibrate treatment (100 mg kg(-1)) produced effects similar to those of Sch B on the hepatic index and lipid levels of hypercholesterolaemic mice." | 1.35 | Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice. ( Dong, H; Fang, HY; Fong, WF; Ko, KM; Pan, SY; Xiang, CJ; Yu, ZL; Zhao, XY, 2008) |
| "Fenofibrate treatment decreased hepatic macrophage accumulation and abolished steatosis." | 1.33 | Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. ( Buffat, L; Gijbels, MJ; Hofker, MH; Maeda, N; Noel, B; Shiri-Sverdlov, R; Staels, B; van Bilsen, M; van Gorp, PJ; Wouters, K, 2006) |
| "Fenofibrate treatment markedly increased circulating resistin levels on both diets and adiponectin levels in chow-fed mice only." | 1.33 | Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. ( Dolinkova, M; Haluzik, M; Haluzik, MM; Haluzikova, D; Horinek, A; Housa, D; Kumstyrova, T; Lacinova, Z; Vernerova, Z, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (40.00) | 29.6817 |
| 2010's | 24 (53.33) | 24.3611 |
| 2020's | 3 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Sashidhara, KV | 1 |
| Kumar, M | 1 |
| Sonkar, R | 1 |
| Singh, BS | 1 |
| Khanna, AK | 1 |
| Bhatia, G | 1 |
| Lefere, S | 1 |
| Puengel, T | 1 |
| Hundertmark, J | 1 |
| Penners, C | 1 |
| Frank, AK | 1 |
| Guillot, A | 1 |
| de Muynck, K | 1 |
| Heymann, F | 1 |
| Adarbes, V | 1 |
| Defrêne, E | 1 |
| Estivalet, C | 1 |
| Geerts, A | 1 |
| Devisscher, L | 1 |
| Wettstein, G | 1 |
| Tacke, F | 1 |
| Shin, Y | 1 |
| Lee, M | 1 |
| Lee, D | 1 |
| Jang, J | 1 |
| Shin, SS | 1 |
| Yoon, M | 1 |
| Olivero-Verbel, J | 1 |
| Harkema, JR | 1 |
| Roth, RA | 1 |
| Ganey, PE | 1 |
| Nikam, A | 1 |
| Patankar, JV | 1 |
| Somlapura, M | 1 |
| Lahiri, P | 1 |
| Sachdev, V | 1 |
| Kratky, D | 1 |
| Denk, H | 1 |
| Zatloukal, K | 1 |
| Abuja, PM | 1 |
| Gao, M | 1 |
| Bu, L | 1 |
| Ma, Y | 1 |
| Liu, D | 1 |
| Hiyama, Y | 1 |
| Marshall, AH | 1 |
| Kraft, R | 1 |
| Arno, A | 1 |
| Jeschke, MG | 1 |
| Pan, SY | 4 |
| Jia, ZH | 2 |
| Zhang, Y | 4 |
| Yu, Q | 1 |
| Wang, XY | 2 |
| Sun, N | 1 |
| Zhu, PL | 2 |
| Yu, ZL | 4 |
| Ko, KM | 4 |
| Karahashi, M | 1 |
| Hoshina, M | 1 |
| Yamazaki, T | 1 |
| Sakamoto, T | 1 |
| Mitsumoto, A | 1 |
| Kawashima, Y | 1 |
| Kudo, N | 1 |
| Eslami, L | 1 |
| Merat, S | 1 |
| Malekzadeh, R | 1 |
| Nasseri-Moghaddam, S | 1 |
| Aramin, H | 1 |
| Sahebkar, A | 1 |
| Chew, GT | 1 |
| Watts, GF | 1 |
| Le, TT | 1 |
| Urasaki, Y | 1 |
| Pizzorno, G | 1 |
| Rull, A | 1 |
| Geeraert, B | 1 |
| Aragonès, G | 1 |
| Beltrán-Debón, R | 1 |
| Rodríguez-Gallego, E | 1 |
| García-Heredia, A | 1 |
| Pedro-Botet, J | 1 |
| Joven, J | 1 |
| Holvoet, P | 1 |
| Camps, J | 1 |
| Yan, F | 1 |
| Wang, Q | 1 |
| Xu, C | 1 |
| Cao, M | 1 |
| Zhou, X | 2 |
| Wang, T | 1 |
| Yu, C | 1 |
| Jing, F | 1 |
| Chen, W | 1 |
| Gao, L | 1 |
| Zhao, J | 1 |
| Chan, SM | 2 |
| Zeng, XY | 2 |
| Sun, RQ | 2 |
| Jo, E | 1 |
| Wang, H | 3 |
| Li, S | 1 |
| Xu, A | 1 |
| Watt, MJ | 2 |
| Ye, JM | 2 |
| Chu, ZS | 1 |
| Wang, XJ | 1 |
| Zhu, YX | 1 |
| Zhang, ML | 1 |
| Zhong, Y | 1 |
| Wang, C | 1 |
| Jia, WP | 1 |
| Rahman, SM | 1 |
| Qadri, I | 1 |
| Janssen, RC | 1 |
| Friedman, JE | 1 |
| Forcheron, F | 1 |
| Abdallah, P | 1 |
| Basset, A | 1 |
| del Carmine, P | 1 |
| Haffar, G | 1 |
| Beylot, M | 1 |
| Kondo, K | 1 |
| Sugioka, T | 1 |
| Tsukada, K | 1 |
| Aizawa, M | 1 |
| Takizawa, M | 1 |
| Shimizu, K | 1 |
| Morimoto, M | 1 |
| Suematsu, M | 1 |
| Goda, N | 1 |
| Fabbrini, E | 1 |
| Mohammed, BS | 1 |
| Korenblat, KM | 1 |
| Magkos, F | 1 |
| McCrea, J | 1 |
| Patterson, BW | 1 |
| Klein, S | 1 |
| Tanaka, N | 1 |
| Zhang, X | 1 |
| Sugiyama, E | 1 |
| Kono, H | 1 |
| Horiuchi, A | 1 |
| Nakajima, T | 2 |
| Kanbe, H | 1 |
| Tanaka, E | 1 |
| Gonzalez, FJ | 1 |
| Aoyama, T | 1 |
| Qi, Z | 1 |
| Xue, J | 1 |
| Xie, M | 1 |
| Lalloyer, F | 2 |
| Wouters, K | 2 |
| Baron, M | 2 |
| Caron, S | 1 |
| Vallez, E | 2 |
| Vanhoutte, J | 1 |
| Baugé, E | 1 |
| Shiri-Sverdlov, R | 2 |
| Hofker, M | 1 |
| Staels, B | 3 |
| Tailleux, A | 2 |
| Leroyer, AS | 1 |
| Majd, Z | 1 |
| Bantubungi, K | 1 |
| Chinetti-Gbaguidi, G | 1 |
| Delerive, P | 1 |
| Boulanger, CM | 1 |
| Kumadaki, S | 1 |
| Karasawa, T | 1 |
| Matsuzaka, T | 1 |
| Ema, M | 1 |
| Nakagawa, Y | 1 |
| Nakakuki, M | 1 |
| Saito, R | 1 |
| Yahagi, N | 1 |
| Iwasaki, H | 1 |
| Sone, H | 1 |
| Takekoshi, K | 1 |
| Yatoh, S | 1 |
| Kobayashi, K | 1 |
| Takahashi, A | 1 |
| Suzuki, H | 1 |
| Takahashi, S | 1 |
| Yamada, N | 1 |
| Shimano, H | 1 |
| Walter, R | 1 |
| Wanninger, J | 1 |
| Bauer, S | 1 |
| Eisinger, K | 1 |
| Neumeier, M | 2 |
| Weiss, TS | 2 |
| Amann, T | 1 |
| Hellerbrand, C | 1 |
| Schäffler, A | 2 |
| Schölmerich, J | 2 |
| Buechler, C | 2 |
| Min, AK | 1 |
| Jeong, JY | 1 |
| Go, Y | 1 |
| Choi, YK | 1 |
| Kim, YD | 1 |
| Lee, IK | 1 |
| Park, KG | 1 |
| Choong, ZH | 1 |
| Yan, M | 1 |
| Meng, FL | 1 |
| Lu, RJ | 1 |
| Jia, XQ | 1 |
| Zhao, XC | 1 |
| van Gorp, PJ | 1 |
| Gijbels, MJ | 1 |
| Noel, B | 1 |
| Buffat, L | 1 |
| Maeda, N | 1 |
| van Bilsen, M | 1 |
| Hofker, MH | 1 |
| Asai, T | 1 |
| Okumura, K | 1 |
| Takahashi, R | 1 |
| Matsui, H | 1 |
| Numaguchi, Y | 1 |
| Murakami, H | 1 |
| Murakami, R | 1 |
| Murohara, T | 1 |
| Athyros, VG | 1 |
| Mikhailidis, DP | 1 |
| Didangelos, TP | 1 |
| Giouleme, OI | 1 |
| Liberopoulos, EN | 1 |
| Karagiannis, A | 1 |
| Kakafika, AI | 1 |
| Tziomalos, K | 1 |
| Burroughs, AK | 1 |
| Elisaf, MS | 1 |
| Haluzik, MM | 1 |
| Lacinova, Z | 1 |
| Dolinkova, M | 1 |
| Haluzikova, D | 1 |
| Housa, D | 1 |
| Horinek, A | 1 |
| Vernerova, Z | 1 |
| Kumstyrova, T | 1 |
| Haluzik, M | 1 |
| Harano, Y | 1 |
| Yasui, K | 1 |
| Toyama, T | 1 |
| Mitsuyoshi, H | 1 |
| Mimani, M | 1 |
| Hirasawa, T | 1 |
| Itoh, Y | 1 |
| Okanoue, T | 1 |
| Weigert, J | 1 |
| Schmidl, C | 1 |
| Büttner, R | 1 |
| Bollheimer, C | 1 |
| Aslanidis, C | 1 |
| Yang, R | 1 |
| Dong, H | 2 |
| Xie, ML | 1 |
| Zhu, LJ | 1 |
| Gu, ZL | 1 |
| Plutzky, J | 1 |
| Zambon, A | 1 |
| Cusi, K | 1 |
| Vilà, L | 1 |
| Roglans, N | 1 |
| Alegret, M | 1 |
| Camins, A | 1 |
| Pallàs, M | 1 |
| Sánchez, RM | 1 |
| Vázquez-Carrera, M | 1 |
| Laguna, JC | 1 |
| Seo, YS | 1 |
| Kim, JH | 1 |
| Jo, NY | 1 |
| Choi, KM | 1 |
| Baik, SH | 1 |
| Park, JJ | 1 |
| Kim, JS | 1 |
| Byun, KS | 1 |
| Bak, YT | 1 |
| Lee, CH | 1 |
| Kim, A | 1 |
| Yeon, JE | 1 |
| Fernández-Miranda, C | 1 |
| Pérez-Carreras, M | 1 |
| Colina, F | 1 |
| López-Alonso, G | 1 |
| Vargas, C | 1 |
| Solís-Herruzo, JA | 1 |
| Zhao, XY | 1 |
| Xiang, CJ | 1 |
| Fang, HY | 1 |
| Fong, WF | 1 |
| Cong, WN | 1 |
| Tao, RY | 1 |
| Tian, JY | 1 |
| Liu, GT | 1 |
| Ye, F | 1 |
2 reviews available for fenofibrate and Liver Steatosis
| Article | Year |
|---|---|
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Topics: Alanine Transaminase; Atorvastatin; Fatty Liver; Fenofibrate; gamma-Glutamyltransferase; Heptanoic A | 2013 |
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Topics: Acetates; Animals; Atherosclerosis; Chalcones; Cholesterol, HDL; Dyslipidemias; Fatty Liver; Fenofib | 2014 |
3 trials available for fenofibrate and Liver Steatosis
| Article | Year |
|---|---|
Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease.
Topics: Adult; Apolipoproteins B; Blood Glucose; Body Composition; Double-Blind Method; Fatty Acids, Noneste | 2010 |
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
Topics: Anti-Obesity Agents; Atorvastatin; Diet, Fat-Restricted; Drug Therapy, Combination; Dyslipidemias; F | 2006 |
A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease.
Topics: Adult; Alkaline Phosphatase; Apolipoprotein A-I; Biopsy, Needle; Dose-Response Relationship, Drug; F | 2008 |
40 other studies available for fenofibrate and Liver Steatosis
| Article | Year |
|---|---|
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
Topics: Animals; Anti-Obesity Agents; Bile Acids and Salts; Butyrates; Dietary Fats; Fatty Liver; Feces; Fee | 2012 |
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
Topics: Animals; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Fatty Liver; | 2020 |
Fenofibrate Regulates Visceral Obesity and Nonalcoholic Steatohepatitis in Obese Female Ovariectomized C57BL/6J Mice.
Topics: Adipocytes; Animals; Diet, High-Fat; Drug Evaluation, Preclinical; Dyslipidemias; Fatty Liver; Femal | 2021 |
Fenofibrate, a peroxisome proliferator-activated receptor-alpha agonist, blocks steatosis and alters the inflammatory response in a mouse model of inflammation-dioxin interaction.
Topics: Alanine Transaminase; Animals; Apoptosis; Dioxins; Disease Models, Animal; Drug Interactions; Fatty | 2021 |
The PPARα Agonist Fenofibrate Prevents Formation of Protein Aggregates (Mallory-Denk bodies) in a Murine Model of Steatohepatitis-like Hepatotoxicity.
Topics: Animals; Disease Models, Animal; Down-Regulation; Fatty Liver; Fenofibrate; Humans; Male; Mallory Bo | 2018 |
Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.
Topics: Adipocytes; Adipose Tissue, White; Animals; Blood Glucose; Cell Size; Cholesterol; Diet, High-Fat; F | 2013 |
Fenofibrate does not affect burn-induced hepatic endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Burns; Endoplasmic Reticulum Stress; Fatty Acids; Fatty Liver; Fenofibrate; Hepa | 2013 |
Novel mouse model of combined hyperlipidemia associated with steatosis and liver injury by a single-dose intragastric administration of schisandrin B/cholesterol/bile salts mixture.
Topics: Administration, Oral; Animals; Bile Acids and Salts; Chemical and Drug Induced Liver Injury; Cholest | 2013 |
Fibrates reduce triacylglycerol content by upregulating adipose triglyceride lipase in the liver of rats.
Topics: Animals; Bezafibrate; Clofibric Acid; Fatty Liver; Fenofibrate; Lipase; Lipid Peroxidation; Liver; M | 2013 |
Uridine prevents fenofibrate-induced fatty liver.
Topics: Acyl-CoA Oxidase; Animals; Biological Transport; Fatty Acids; Fatty Liver; Fenofibrate; Gene Express | 2014 |
Rosiglitazone and fenofibrate exacerbate liver steatosis in a mouse model of obesity and hyperlipidemia. A transcriptomic and metabolomic study.
Topics: Animals; Disease Models, Animal; Fatty Liver; Fenofibrate; Gene Expression Profiling; Gene Expressio | 2014 |
Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect.
Topics: Animals; Dose-Response Relationship, Drug; Fatty Liver; Fenofibrate; Gene Expression Regulation; Hep | 2014 |
Fenofibrate insulates diacylglycerol in lipid droplet/ER and preserves insulin signaling transduction in the liver of high fat fed mice.
Topics: Animals; Diet, High-Fat; Diglycerides; Endoplasmic Reticulum; Fatty Liver; Fenofibrate; Hypolipidemi | 2015 |
A comparative study between Wuweizi seed and its post-ethanol extraction residue in normal and hypercholesterolemic mice.
Topics: Adipose Tissue; Animals; Anticholesteremic Agents; Blood Glucose; Body Weight; Cholesterol, Dietary; | 2015 |
Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver.
Topics: Animals; Diet, High-Fat; Fatty Liver; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents | 2016 |
Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis.
Topics: AMP-Activated Protein Kinases; Blotting, Western; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding | 2009 |
Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Disease Models, Animal; Eating | 2009 |
Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice.
Topics: Animals; Dietary Fats; Fatty Liver; Fenofibrate; Liver; Male; Mice; Mice, Inbred C57BL; Microcircula | 2010 |
Eicosapentaenoic acid improves hepatic steatosis independent of PPARα activation through inhibition of SREBP-1 maturation in mice.
Topics: Animals; Dietary Fats; Disease Models, Animal; Eicosapentaenoic Acid; Fatty Liver; Fenofibrate; Geno | 2010 |
Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats.
Topics: Adiponectin; Animals; Blood Glucose; Cnidium; Coumarins; Dietary Fats; Dietary Sucrose; Fatty Liver; | 2011 |
Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents; Aorta; Apolipoprotein E2; Atherosclerosis; | 2011 |
PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH.
Topics: Animals; Atherosclerosis; Biomarkers; Cell-Derived Microparticles; Disease Models, Animal; Fatty Liv | 2011 |
Inhibition of ubiquitin ligase F-box and WD repeat domain-containing 7α (Fbw7α) causes hepatosteatosis through Krüppel-like factor 5 (KLF5)/peroxisome proliferator-activated receptor γ2 (PPARγ2) pathway but not SREBP-1c protein in mice.
Topics: Animals; Cell Cycle; Cell Proliferation; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Fatty | 2011 |
Adiponectin reduces connective tissue growth factor in human hepatocytes which is already induced in non-fibrotic non-alcoholic steatohepatitis.
Topics: Adiponectin; Anticholesteremic Agents; Connective Tissue Growth Factor; Down-Regulation; Fatty Liver | 2011 |
cAMP response element binding protein H mediates fenofibrate-induced suppression of hepatic lipogenesis.
Topics: Animals; Cell Line; Cell Line, Tumor; Cyclic AMP Response Element-Binding Protein; Fatty Liver; Feno | 2013 |
Activation of PPARα ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress.
Topics: Animals; Endoplasmic Reticulum Stress; Fatty Acids; Fatty Liver; Fenofibrate; Fructose; Insulin Resi | 2013 |
[Therapy effects of fenofibrate on alcoholic fatty liver and drug-induced fatty liver in rats].
Topics: Animals; Carbon Tetrachloride; Fatty Liver; Fatty Liver, Alcoholic; Fenofibrate; Hypolipidemic Agent | 2003 |
Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates.
Topics: Animals; Apolipoprotein E2; Apolipoproteins E; ATP-Binding Cassette Transporters; Clofibric Acid; Di | 2006 |
Combined therapy with PPARalpha agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency.
Topics: Adenosine Triphosphate; Animals; Cardiomyopathy, Hypertrophic; Carnitine; Diglycerides; Drug Therapy | 2006 |
Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.
Topics: Adiponectin; Adipose Tissue; Animals; Blood Glucose; Diet; Dietary Carbohydrates; Fatty Acids, Nones | 2006 |
Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
Topics: Animals; Catalase; Fatty Acids; Fatty Liver; Fenofibrate; Gene Expression Regulation; Lipid Peroxida | 2006 |
Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro.
Topics: Adiponectin; Aldehyde Oxidoreductases; Animals; Cells, Cultured; Dose-Response Relationship, Drug; D | 2006 |
Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice.
Topics: Animals; Bile Acids and Salts; Biphenyl Compounds; Cholesterol; Cholesterol, Dietary; Disease Models | 2006 |
Therapeutic effect of osthole on hyperlipidemic fatty liver in rats.
Topics: Animals; Antioxidants; Cnidium; Coumarins; Fatty Liver; Fenofibrate; Hyperlipidemias; Hypolipidemic | 2007 |
Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARalpha.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fatty Liver; Fen | 2007 |
The role of fenofibrate in clinical practice.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination | 2007 |
Hypertriglyceridemia and hepatic steatosis in senescence-accelerated mouse associate to changes in lipid-related gene expression.
Topics: Aging; Analysis of Variance; Animals; Blotting, Western; Fatty Liver; Fenofibrate; Gene Expression R | 2007 |
PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
Topics: Animals; Disease Models, Animal; Fatty Acids; Fatty Liver; Fenofibrate; Gene Expression Profiling; H | 2008 |
Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice.
Topics: Animals; Bile Acids and Salts; Cholesterol; Cholesterol, Dietary; Cyclooctanes; Disease Models, Anim | 2008 |
The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Topics: Animals; Dietary Fats; Disease Models, Animal; Fatty Acids; Fatty Liver; Fenofibrate; Gene Expressio | 2008 |